Full Press Release Details
Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Angeles, CA -- June 8, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes" or "Company") - a pioneer
of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of
its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant.
Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common
stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance and all shares of common
stock and warrants that comprise the units are being issued as separate securities. The public offering price for a unit is $18.00.
gross proceeds from the offering are expected to be approximately $5.33 million before deducting underwriting discounts, commissions,
and estimated offering expenses. The offering is expected to close on June 9, 2026, subject to satisfaction of customary closing conditions.
The Company has also granted the underwriter a 45 day option to purchase up to 44,420 units at the unit offering price, less underwriting
discounts and commissions, solely to cover over-allotments, if any.
warrant will be exercisable commencing the first anniversary of the date of this offering at an exercise price of $11.24 per share and
will expire five years from the date of issuance. Commencing from the date they become exercisable, the warrants may be redeemed
by the Company, for $0.01 per underlying share, if the Company's common stock trades at a price of $17.98 per share or higher (subject
to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions after the initial exercise
date), on any twenty (20) trading days during any thirty (30) trading day period. The exercise price of a warrant may be reset to $0.001
per underlying share, if within 12 months of the offering the Company sells in a public or private offering additional shares of common
stock, or preferred stock or other securities convertible into shares of common stock, at a price (or equivalent) that is less than $8.99
per share. To qualify for the warrant reset, if any, an original purchaser of a unit in this offering must hold and not sell all the
shares of common stock purchased in this offering up until the date of the warrant reset event. The warrants will not be listed on any
national trading market or other trading medium.
intends to use the net proceeds from this offering to further develop N-trans-caffeoyltyramine (NCT) opportunities associated with our
NCT business and products developed under the NCT technology, next in line products, research and development, and for general corporate
purposes, working capital purposes and capital expenditures.
Capital is acting as underwriter and sole book-running manager for this offering.
registration statement on Form S-3 (File No. 333-292781) relating to the securities was filed with the Securities and Exchange
Commission ("SEC") and became effective on January 23, 2026. This offering is being made only by means of a prospectus supplement
and the accompanying base prospectus that form a part of that registration statement. Copies of the final prospectus supplement, when
available, may be obtained from MDB Capital at 14135 Midway Road, Suite G-150, Addison, Texas 75001. The final prospectus supplement
will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.
press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design,
engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable,
sustainable, and abundant alternative: exozymes.
are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace
toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant
feedstock into valuable nutraceuticals and novel medicines.
freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck
that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
eXoZymes Inc. has introduced "exozymes" as a scientific concept, the company is not trademarking the concept and views it
as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and of which it intends
to be the market leader.
more at exozymes.com
press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally
be identified by the use of forward-looking terms such as "believe," "expect," "may," "will,"
"should," "would," "could," "seek," "intend," "plan," "goal,"
"project," "estimate," "anticipate," "strategy," "future," "likely,"
"potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All
statements other than statements of historical facts included in this press release regarding the company's strategies, prospects,
financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for
a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of
eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time
by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that
could cause actual events and results to differ materially from those contained in the forward-looking statements. Certain forward-looking
statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are
described more fully in the section titled "Risk Factors" in the final prospectus related to the public offering that will
be filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give
any assurance that it will achieve its expectations.
G rlitz, VP of Comms & IR